<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0"><akn:act><akn:meta><akn:identification source="#cosilico"><akn:FRBRWork prescriptive="true" authoritative="true"><akn:FRBRuri value="/akn/us/usc/42/299b–1" /><akn:FRBRdate date="2025-12-31" name="retrieval" /><akn:FRBRauthor href="#us-congress" /><akn:FRBRcountry value="us" /></akn:FRBRWork><akn:FRBRExpression><akn:FRBRuri value="/akn/us/usc/42/299b–1/eng@2025" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /><akn:FRBRlanguage language="en" /></akn:FRBRExpression><akn:FRBRManifestation><akn:FRBRuri value="/akn/us/usc/42/299b–1/eng@2025/main.xml" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /></akn:FRBRManifestation></akn:identification></akn:meta><akn:body><akn:section eId="sec_299b_1"><akn:num>299b–1</akn:num><akn:heading>Private-public partnerships to improve organization and delivery</akn:heading><akn:content><akn:p>§ 299b–1. Private-public partnerships to improve organization and delivery(a) Support for efforts to develop information on quality(1) Scientific and technical supportIn its role as the principal agency for health care research and quality, the Agency may provide scientific and technical support for private and public efforts to improve health care quality, including the activities of accrediting organizations.


(2) Role of the AgencyWith respect to paragraph (1), the role of the Agency shall include—(A) the identification and assessment of methods for the evaluation of the health of—(i) enrollees in health plans by type of plan, provider, and provider arrangements; and

(ii) other populations, including those receiving long-term care services;


(B) the ongoing development, testing, and dissemination of quality measures, including measures of health and functional outcomes;

(C) the compilation and dissemination of health care quality measures developed in the private and public sector;

(D) assistance in the development of improved health care information systems;

(E) the development of survey tools for the purpose of measuring participant and beneficiary assessments of their health care; and

(F) identifying and disseminating information on mechanisms for the integration of information on quality into purchaser and consumer decision-making processes.



(b) Centers for education and research on therapeutics(1) In generalThe Secretary, acting through the Director and in consultation with the Commissioner of Food and Drugs, shall establish a program for the purpose of making one or more grants for the establishment and operation of one or more centers to carry out the activities specified in paragraph (2).


(2) Required activitiesThe activities referred to in this paragraph are the following:(A) The conduct of state-of-the-art research for the following purposes:(i) To increase awareness of—(I) new uses of drugs, biological products, and devices;

(II) ways to i</akn:p></akn:content><akn:subsection eId="subsec_299b_1_a"><akn:num>(a)</akn:num><akn:heading>Support for efforts to develop information on quality</akn:heading><akn:content><akn:p>(a) Support for efforts to develop information on quality</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_299b_1_b"><akn:num>(b)</akn:num><akn:heading>Centers for education and research on therapeutics</akn:heading><akn:content><akn:p>(b) Centers for education and research on therapeutics</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_299b_1_c"><akn:num>(c)</akn:num><akn:heading>Reducing errors in medicine</akn:heading><akn:content><akn:p>(c) Reducing errors in medicine The Director shall, in accordance with part C, conduct and support research and build private-public partnerships to—</akn:p></akn:content></akn:subsection></akn:section></akn:body></akn:act></akn:akomaNtoso>